Treatment of graft-versus-host-disease with mesenchymal stromal cells

References

• Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, . Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002; 418:41–9.
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, . Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005;7:393–5.
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, . Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11–20.
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, . Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838–43.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105:1815–22.
   PubMed Web of Science ®Google Scholar
• Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726–36.
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol. 2008;251:131–6.
   PubMed Web of Science ®Google Scholar
• Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 2000;28:875–84.
   PubMed Web of Science ®Google Scholar
• Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105:93–8.
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, . Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA. 2002;99:8932–7.
   PubMed Web of Science ®Google Scholar
• Robinson SN, Ng J, Niu T, Yang H, McMannis JD, Karandish S, . Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant. 2006;37:359–66.
   PubMed Web of Science ®Google Scholar
• McNiece I, Harrington J, Turney J, Kellner J, Shpall EJ. Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells. Cytotherapy. 2004;6:311–7.
   PubMed Web of Science ®Google Scholar
• Najar M, Raicevic G, Boufker HI, Fayyad Kazan H, De Bruyn C, Meuleman N, . Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's jelly and bone marrow sources. Cell Immunol. 2010;264:171–9.
   PubMed Web of Science ®Google Scholar
• Majore I, Moretti P, Stahl F, Hass R, Kasper C. Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord. Stem Cell Rev. 2010; in press.
   Google Scholar
• Najar M, Raicevic G, Boufker HI, Fayyad-Kazan H, De Bruyn C, Meuleman N, . Adipose-tissue-derived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng Part A. 2010;16:3537–46.
   PubMed Web of Science ®Google Scholar
• Tong CK, Vellasamy S, Tan BC, Abdullah M, Vidyadaran S, Seow HF, . Generation of mesenchymal stem cell from human umbilical cord tissue using a combination of enzymatic and mechanical disassociation method. Cell Biol Int. 2010; in press.
   Google Scholar
• Zhang Y, Li C, Jiang X, Zhang S, Wu Y, Liu B, . Human placenta-derived mesenchymal progenitor cells support culture expansion of long-term culture-initiating cells from cord blood CD34+ cells. Exp Hematol. 2004;32:657–64.
   PubMed Web of Science ®Google Scholar
• Auletta JJCK, Solchaga LA, Deans RJ, vant Hof W. Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions. Biol Blood Marrow Transplant. 2010;16:891–906.
   PubMedGoogle Scholar
• Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7:340–52.
   PubMed Web of Science ®Google Scholar
• Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 2006;107:1484–90.
   PubMed Web of Science ®Google Scholar
• Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139–70.
   PubMed Web of Science ®Google Scholar
• Keating A. How do mesenchymal stromal cells suppress T cells? Cell Stem Cell. 2008;2:106–8.
   PubMed Web of Science ®Google Scholar
• Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell–lymphocyte interaction. Haematologica. 2007;92:881–8.
   PubMedGoogle Scholar
• Sundin M, Barrett AJ, Ringden O, Uzunel M, Lonnies H, Dackland AL, . HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother. 2009; 32:755–64.
   PubMed Web of Science ®Google Scholar
• Li J, Zhu H, Liu Y, Li Q, Lu S, Feng M, . Human mesenchymal stem cell transplantation protects against cerebral ischemic injury and upregulates interleukin-10 expression in Macacafascicularis. Brain Res. 2010;1334:65–72.
   PubMed Web of Science ®Google Scholar
• Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood. 2003;101:2999–3001.
   PubMed Web of Science ®Google Scholar
• Chapel A, Bertho JM, Bensidhoum M, Fouillard L, Young RG, Frick J, . Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med. 2003;5:1028–38.
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004;95:9–20.
   PubMed Web of Science ®Google Scholar
• Prockop DJ, Olson SD. Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions. Blood. 2007;109:3147–51.
   PubMed Web of Science ®Google Scholar
• Ball L, Bredius R, Lankester A, Schweizer J, van den Heuvel-Eibrink M, Escher H, . Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia. Leukemia. 2008;22:1256–7.
   PubMedGoogle Scholar
• Chung NG, Jeong DC, Park SJ, Choi BO, Cho B, Kim HK, . Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation. Int J Hematol. 2004;80:370–6.
   PubMed Web of Science ®Google Scholar
• Sudres M, Norol F, Trenado A, Gregoire S, Charlotte F, Levacher B, . Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol. 2006;176:7761–7.
   PubMed Web of Science ®Google Scholar
• Tisato V, Naresh K, Girdlestone J, Navarrete C, Dazzi F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia. 2007;21:1992–9.
   PubMed Web of Science ®Google Scholar
• Min CK, Kim BG, Park G, Cho B, Oh IH. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39:637–45.
   PubMed Web of Science ®Google Scholar
• Joo SY, Cho KA, Jung YJ, Kim HS, Park SY, Choi YB, . Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner. Cytotherapy. 2010;12: 361–70.
   PubMed Web of Science ®Google Scholar
• Ye Z, Wang Y, Xie HY, Zheng SS. Immunosuppressive effects of rat mesenchymal stem cells: involvement of CD4+ CD25+ regulatory T cells. Hepatobiliary Pancreat Dis Int. 2008;7: 608–14.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rey E, Gonzalez MA, Varela N, O'Valle F, Hernandez-Cortes P, Rico L, . Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis. 2010;69:241–8.
   PubMed Web of Science ®Google Scholar
• Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, . Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol. 2008;181:3933–46.
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini D, . Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol. 2008;36:309–18.
   PubMed Web of Science ®Google Scholar
• Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, . IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008;38:1745–55.
   PubMed Web of Science ®Google Scholar
• Croitoru-Lamoury J, Lamoury FM, Zaunders JJ, Veas LA, Brew BJ. Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone. J Interferon Cytokine Res. 2007;27:53–64.
   PubMed Web of Science ®Google Scholar
• New JY, Li B, Koh WP, Ng HK, Tan SY, Yap EH, . T cell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease. Bone Marrow Transplant. 2002;29:979–86.
   PubMed Web of Science ®Google Scholar
• Wang L, Li Y, Chen X, Chen J, Gautam SC, Xu Y, . MCP-1, MIP-1, IL-8 and ischemic cerebral tissue enhance human bone marrow stromal cell migration in interface culture. Hematology. 2002;7:113–7.
   PubMedGoogle Scholar
• Zhang W, Ge W, Li C, You S, Liao L, Han Q, . Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 2004;13:263–71.
   PubMed Web of Science ®Google Scholar
• Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, . Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 2005;105:2214–9.
   PubMed Web of Science ®Google Scholar
• Gur-Wahnon D, Borovsky Z, Beyth S, Liebergall M, Rachmilewitz J. Contact-dependent induction of regulatory antigen-presenting cells by human mesenchymal stem cells is mediated via STAT3 signaling. Exp Hematol. 2007;35: 426–33.
   PubMed Web of Science ®Google Scholar
• Joo SY, Cho KA, Jung YJ, Kim HS, Park SY, Choi YB, . Bioimaging to monitor the in vivo distribution of infused mesenchymal stem cells: in a mouse model of graft versus host disease. Cell Biol Int. 2010; in press.
   Google Scholar
• Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs. 2001;169:12–20.
   PubMed Web of Science ®Google Scholar
• Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, . Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5:54–63.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, . Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–41.
   PubMed Web of Science ®Google Scholar
• Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, . Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390–7.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, . Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–86.
   PubMed Web of Science ®Google Scholar
• Kurtzberg J, Prasad V, Grimley MS, Horn B, Carpenter PA, Jacobsen D, Prockop S. Allogeneic Human Mesenchymal Stem Cell Therapy (Prochymal) as a Rescue Agent for Severe Treatment Resistant GVHD in Pediatric Patients. Orlando: American Society of Blood and Marrow Transplantation; 2009.
   Google Scholar
• von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N, Holig K, . Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 2009;43:245–51.
   PubMed Web of Science ®Google Scholar
• Muller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoeffer F, . Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis. 2008;40:25–32.
   PubMed Web of Science ®Google Scholar
• Fang B, Song Y, Zhao RC, Han Q, Lin Q. Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis. Transplant Proc. 2007;39:1710–3.
   PubMed Web of Science ®Google Scholar
• Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, . Efficacy and safety of ex-vivo cultured adult human mesenchymal stem cells (Prochymal (TM)) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant. 2010; in press.
   PubMedGoogle Scholar
• Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, . Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009;15:804–11.
   PubMed Web of Science ®Google Scholar
• Martin BJ, Uberti JP, Soiffer RJ, Klingemann H, Waller EK, Daly AS, . Prochymal Improves Response Rates in Patients with Steroid-Refractory Acute Graft versus Host Disease (SR-GVHD) involving the Liver and Gut: Results of a Randomized, Placebo-Controlled, Multicenter Phase III Trial in GVHD. Orlando: American Society of Bone Marrow Transplantation; 2010.
   Google Scholar
• Lucchini G, Introna M, Dander E, Rovelli A, Balduzzi A, Bonanomi S, . Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant. 2010;16:1293–301.
   PubMed Web of Science ®Google Scholar
• Zhou H, Guo M, Bian C, Sun Z, Yang Z, Zeng Y, . Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant. 2010;16: 403–12.
   PubMed Web of Science ®Google Scholar